Thomas Neumann

Title: Thomas Neumann: Innovator in Cell Disruption Technologies

Introduction

Thomas Neumann is a notable inventor based in Frankfurt-am-Main, Germany. He has made significant contributions to the field of biotechnology, particularly in methods for disrupting cells and tissues. With a total of 2 patents, his work has implications for both pharmaceutical and agricultural applications.

Latest Patents

Neumann's latest patents include a method for disrupting frozen cells and/or tissue in a solid, frozen state in the presence of a solid denaturing substance. This innovative method involves providing frozen cells and/or tissue, adding a solid denaturing substance, and applying mechanical force for disruption. The frozen cells can include muscle cells, wheat cells, and maize cells. The solid denaturing substances he utilizes can be crystalline and include urea, thiourea, guanidium chloride, guanidium thiocyanate, and ammonium sulfate. His second patent relates to a poly(A)-specific 3′-exonuclease activity, which can be obtained by purifying a crude extract of animal or human cells. This invention has potential uses in deadenylating 3′-poly(A) tails of nucleic acids and serves as a pharmaceutical or diagnostic agent.

Career Highlights

Thomas Neumann is currently employed at Aventis Research & Technologies GmbH & Co. KG, where he continues to develop innovative solutions in biotechnology. His work is characterized by a strong focus on practical applications that can benefit various industries.

Collaborations

Neumann collaborates with esteemed colleagues such as Stefan Müllner and Christoph Hüls, contributing to a dynamic research environment that fosters innovation.

Conclusion

Thomas Neumann's contributions to biotechnology through his patents and collaborative efforts highlight his role as a significant inventor in the field. His innovative methods for cell disruption and nucleic acid processing are paving the way for advancements in both medical and agricultural sciences.